DataLookout › Non-Hodgkin Lymphoma › MCL Clinical Trials

Mantle Cell Lymphoma Clinical Trial Landscape

MCL treatment is entering its third generation — from covalent BTK inhibitors to non-covalent inhibitors to BTK degraders, with CAR-T and bispecific antibodies reshaping the relapsed setting. Get daily alerts for the trials defining MCL care in 2026.

Track MCL Trials Free

Active Phase 3 MCL Programs (2026)

NCT IDDrug / MechanismSponsorPhaseStatus
NCT06742996 Sonrotoclax (BGB-11417) + zanubrutinib vs. placebo + zanubrutinib — BCL-2 inhibitor + BTKi in R/R MCL (CELESTIAL-RRMCL) BeOne Medicines Phase 3 Recruiting

Active Phase 2 Programs

NCT IDDrug / MechanismSponsorStatus
NCT05529069 Pirtobrutinib + venetoclax — non-covalent BTKi + BCL-2i in R/R MCL MD Anderson Cancer Center Recruiting
NCT06263491 Pirtobrutinib + rituximab — non-covalent BTKi in previously untreated low/intermediate-risk MCL MD Anderson Cancer Center Recruiting
NCT07003295 Glofitamab — CD20xCD3 bispecific T-cell engager in MCL after CAR-T failure NCI Recruiting

Active Phase 1 / Early Programs

NCT IDDrug / MechanismSponsorStatus
NCT05006716 BGB-16673 — BTK CDAC protein degrader in R/R B-cell malignancies including MCL BeOne Medicines Recruiting
NCT04830137 NX-2127 — BTK/IKZF1/IKZF3 degrader in R/R B-cell malignancies including MCL Nurix Therapeutics Recruiting
NCT06026319 CD79b-19 CAR T cells — dual-antigen CAR-T in Non-Hodgkin Lymphoma including MCL Mass General / MGH Cancer Center Recruiting

Track MCL Trials

When CELESTIAL-RRMCL opens new sites or pirtobrutinib combination data is updated, you'll know the same day.

Start Free — No Credit Card

The MCL Treatment Landscape in 2026: The BTK Evolution

Mantle cell lymphoma is a mature B-cell lymphoma defined by the t(11;14) translocation — overexpression of cyclin D1 due to juxtaposition with the IGH locus. Despite being relatively uncommon (approximately 6% of all NHL cases), MCL has been a proving ground for some of oncology's most consequential drug classes.

The BTK inhibitor story in MCL illustrates the generation-by-generation evolution of targeted therapy: ibrutinib (first-generation, covalent) → acalabrutinib/zanubrutinib (second-generation covalent, improved selectivity) → pirtobrutinib (non-covalent, works in C481S-mutated BTKi-resistant disease) → BTK degraders (eliminate the entire protein, mechanism-agnostic resistance). Each step was driven by the prior generation's resistance mechanisms.

Why BeOne Medicines Dominates the MCL Trial Landscape

BeOne (formerly BeiGene) has two approved MCL drugs — zanubrutinib (Brukinsa, BTK inhibitor) and tislelizumab (PD-1 checkpoint inhibitor) — and two investigational agents in MCL-relevant trials: sonrotoclax (BCL-2 inhibitor) and BGB-16673 (BTK degrader). The CELESTIAL-RRMCL Phase 3 trial is the direct test of BeOne's hypothesis that their proprietary BTKi + BCL-2i combination is superior to BTKi monotherapy — a strategy similar to the venetoclax + ibrutinib (VenEx) combinations studied in CLL, but using next-generation agents with potentially improved tolerability profiles.

The Post-CAR-T Problem in MCL

KTE-X19 (Tecartus) CAR-T produces high response rates in R/R MCL but durability is a challenge — approximately 50% of responders eventually relapse. The post-CAR-T setting is emerging as MCL's newest unmet need as more patients receive CAR-T in earlier lines. The NCI glofitamab trial (NCT07003295) directly addresses post-CAR-T MCL: rather than infusing CAR-T cells again (logistically challenging post-lymphodepletion), a bispecific T-cell engager redirects endogenous T cells to CD20+ tumor cells. This is particularly relevant because CD19-targeted approaches (like many CAR-T products) can select for CD19-negative escape — whereas glofitamab targets CD20, a distinct B-cell antigen.

FAQ

Frequently asked questions

What is sonrotoclax and what does the CELESTIAL-RRMCL Phase 3 trial test?
Sonrotoclax (BGB-11417) is BeOne Medicines's BCL-2 inhibitor, designed as a next-generation successor to venetoclax. BCL-2 (B-cell lymphoma 2) is an anti-apoptotic protein highly expressed in mantle cell lymphoma (MCL) that helps tumor cells evade programmed cell death. Venetoclax (Venclexta) is approved in CLL and AML and has shown activity in MCL off-label, but has no MCL-specific approval. The CELESTIAL-RRMCL Phase 3 trial (NCT06742996) tests sonrotoclax in combination with zanubrutinib (BeOne's BTK inhibitor, approved in MCL as Brukinsa) versus placebo plus zanubrutinib in adults with relapsed/refractory MCL. Early-phase data combining the two drugs reported response rates in the high 70s to low 80s percent. If positive, CELESTIAL-RRMCL would support a new combination standard of care in relapsed/refractory MCL.
What is pirtobrutinib (Jaypirca) and how does it work in BTK-inhibitor-resistant MCL?
Pirtobrutinib (Jaypirca, Eli Lilly) is a non-covalent BTK inhibitor: it binds BTK reversibly rather than forming the covalent bond at C481 that ibrutinib, acalabrutinib, and zanubrutinib require. This matters because the most common resistance mechanism to covalent BTK inhibitors is the C481S mutation in BTK, which prevents covalent bond formation and blocks drug binding. Pirtobrutinib binds BTK independently of C481S status, restoring kinase inhibition in cells that have evolved covalent-BTKi resistance. The FDA approved pirtobrutinib in January 2023 for relapsed/refractory MCL after at least two prior lines of therapy, including a covalent BTK inhibitor, based on the BRUIN trial (overall response rate 50%, complete response 13%, in patients previously treated with a covalent BTK inhibitor).
What is a BTK protein degrader, and how do investigational degraders differ from BTK inhibitors?
BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) block BTK's kinase activity but leave the BTK protein intact, which allows resistance through protein overexpression, kinase-domain bypass mutations, or non-kinase BTK scaffolding functions. BTK degraders use a PROTAC (proteolysis-targeting chimera) or molecular-glue approach: they recruit a cell's own protein-disposal machinery to mark the BTK protein for degradation, eliminating the entire protein rather than just its activity. Several BTK degraders (from BeOne Medicines and Nurix Therapeutics, among others) are in early-phase trials in relapsed/refractory B-cell malignancies including MCL. The hypothesis is that degraders could overcome both C481S and non-C481S BTKi resistance by eliminating the protein entirely, regardless of mutation status.
What role does CAR-T cell therapy play in MCL?
Brexucabtagene autoleucel (Tecartus, KTE-X19) is an approved CAR-T therapy in MCL, initially approved in 2020 for relapsed/refractory MCL after two or more prior lines of therapy, later receiving full approval. In the pivotal ZUMA-2 trial cohort of BTK-inhibitor-exposed patients, it produced an overall response rate of 87% and a complete response rate of 62%. Roughly half of patients who respond will eventually relapse, and the post-CAR-T setting in MCL has no established standard of care; bispecific T-cell engagers and other novel agents are being investigated for patients who progress after CAR-T.
What is the current standard of care for mantle cell lymphoma?
MCL treatment is broadly stratified by patient fitness and line of therapy. For transplant-eligible patients in first-line treatment, intensive chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) remains a standard for young, fit patients, though this is increasingly challenged by frontline BTK-inhibitor-containing regimens. Transplant-ineligible patients typically receive chemoimmunotherapy such as R-CHOP or bendamustine plus rituximab. In relapsed/refractory MCL, covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are generally used first; after progression on a covalent BTK inhibitor, options include pirtobrutinib or brexucabtagene autoleucel (CAR-T) if the patient has had two or more prior lines. After CAR-T failure, there is no established standard of care, and enrollment in a clinical trial is often recommended.

Track the CELESTIAL-RRMCL Phase 3 Trial

When BeOne posts enrollment updates or site openings for the sonrotoclax + zanubrutinib trial, get the alert the same day.

Start Free — No Credit Card

Related Pages

Live trial data Data as of 2026-08-28, ClinicalTrials.gov

198 active trials, 100 recruiting. Phases: Early Phase 1: 1, Phase 1: 80, Phase 2: 116, Phase 3: 9, Phase 4: 1.

Top sponsorTrials
BeOne Medicines4
Guangzhou Lupeng Pharmaceutical Company LTD.3
Nurix Therapeutics, Inc.2
Acerta Pharma BV2
AstraZeneca2

View the full sponsor pipeline on the dashboard

Notable trials Ranked by recent tracked changes, ClinicalTrials.gov data as of 2026-08-28
TrialStatusLatest tracked changeSeen
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of… NCT04626791Active, Not RecruitingPrimary endpoint(s) modified2026-08-26
Consolidation With Loncastuximab Tesirine After a Short Course of… NCT05249959Active, Not RecruitingPrimary completion pushed: 2026-03-21 → 2027-032026-08-25
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in… NCT05006716RecruitingPrimary endpoint(s) modified2026-08-22
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With… NCT04007029Active, Not RecruitingCompletion pushed: 2027-08-01 → 2028-08-012026-08-21
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma NCT07673367RecruitingRecruitment opened2026-08-06

Each trial page shows every change DataLookout has recorded for that trial.

Track these trials with DataLookout

DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.

Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search with email alerts, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.

Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches with email alerts, track up to 25 individual trials, full Trials at Risk list and landscape reports.

Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.

Start free